Search

Filters

Clear Filters
11:25 AM - 11:35 AM ET

169 - A Novel Regimen of Liposomal Irinotecan Plus Capecitabine as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LipCap): A Phase II Trial
Speaker: Xiao, Linlin, MS, RT - the fourth hospital of hebei medical university, Shijiazhuang, Hebei province
11:35 AM - 11:45 AM ET

170 - KRAS Variant-Specific Chemoradiation Response and Tumor Microenvironment Characterization in Locally Advanced Rectal Cancer: An Integrated Transcriptomic Profiling
Speaker: Lasington, Jeril, MD - NYMC-Saint Clare's Health and Saint Mary's general hospital, Denville, NJ
10:45 AM - 10:55 AM ET

172 - Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile
Speaker: Liu, Feng, MD - Hunan Cancer Hospital, Changsha, Hunan
10:55 AM - 11:05 AM ET

173 - C-Post Study of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma: Impact of Adjuvant Radiotherapy on Disease-Free Survival
Speaker: Porceddu, Sandro, MD - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC
11:05 AM - 11:15 AM ET

174 - Secondary Immunological Analysis of a Prospective Trial in Patients with Recurrent Head and Neck Malignancies
Speaker: Unnikrishnan, Soumya, MD, MS - Winship Cancer Institute of Emory University, Atlanta, GA
11:15 AM - 11:25 AM ET

175 - Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: 3-Year Follow-Up of the INSIGHT Study
Speaker: Ou, Xiaomin, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
11:25 AM - 11:35 AM ET

176 - Efficacy and Safety of an Adaptive Treatment Strategy for Locoregionally Advanced Nasopharyngeal Carcinoma Based on Response Stratification to Nimotuzumab Plus Induction Chemotherapy: A Prospective Multicenter Phase II Clinical Study
Speaker: Zeng, Lei, MD - The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi
10:45 AM - 10:55 AM ET

177 - "No Phase III? No Worries!": Analysis of over 1100 Inoperable Early-Stage Lung Cancer Patients Treated with Either Single- or Three-Fraction SBRT to Reveal a Standard of Care
Speaker: Videtic, Gregory, MD, FASTRO, CM, FRCPC, FACR - Cleveland Clinic, Cleveland Heights, OH
10:55 AM - 11:05 AM ET

178 - A Dose Escalation Study of Papaverine As a Selective Hypoxic Radiosensitizer for Lung Stereotactic Body Radiation Therapy (SBRT) In the Treatment of Early-Stage Non-Small Cell Lung Cancer (NSCLC) and Other Malignancies
Speaker: Brownstein, Jeremy, MD, MS - Ohio State University James Cancer Hospital, Columbus, OH
11:05 AM - 11:15 AM ET

179 - Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes
Speaker: Oska, Caroline, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx, NY
11:15 AM - 11:25 AM ET

180 - Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
Speaker: Wang, Linlin, MD, PhD - Shandong Cancer Hospital and Institute, Jinan
11:25 AM - 11:35 AM ET

181 - Risk-Adapted Radiotherapy for Locally Advanced NSCLC: Pooled Analysis of Two Prospective Trials
Speaker: Saad, Shumaila, MD - Montefiore Medical Center, Bronx, NY